Newron Pharmaceuticals - Xadago slows, Evenamide lags but STARS ahead
Newron Pharmaceuticals’ interim results highlight that despite additional worldwide launches of Xadago, sales growth in the US and Europe remain...
1.2k Views
Newron Pharmaceuticals - 2018 focus on the CNS pipeline
Xadago for Parkinson’s disease (PD) is now available in 14 European countries through partner, Zambon. Additionally, the drug is available in the...
83 Views
Xadago launched; eyes now on pipeline assets
Following an encouraging year to date we have upgraded our forecasts for Xadago (Parkinson’s disease [PD] therapy), and key CNS pipeline assets...
87 Views
Xadago receives FDA approval in PD
Newron and its partners Zambon and US WorldMeds have announced that the FDA has approved Xadago (safinamide) for Parkinson’s disease (PD) patients...
156 Views
Marching into 2017
We anticipate that the sales and pipeline progression made by Newron in 2016 will be cemented further in 2017/18. A critical catalyst remains the...
40 Views